Lactobacillus rhamnosus, lactobacillus reuteri, probiotic formula thereof, preparation method and application of probiotic formula
Patents no.: CN111500483B
Bacterial Vaginosis (BV) is the most common vaginal infectious disease for women at childbearing age, and the infection rate in China is about 15-50%, wherein about 10-40% of BV is asymptomatic. BV is mainly characterized by a decrease in the number of vaginal lactobacilli, while other vaginal microorganisms such as Gardner bacteria, or mixed anaerobic bacteria such as gram-positive anaerobacter Peptococcus (Peptococcus), Peptostreptococcus (Peptostreptococcus), gram-negative anaerobacter Bacteroides (Bacteroides) multiply in large numbers to cause vaginal dysbacteriosis.
Vulvovaginal Candidiasis (VVC) is also a common vaginal infectious disease in women, and the most common pathogenic bacteria are Candida albicans. VVC is in the 2 nd place of female genital tract infection disease, is second to BV, and has high recurrence rate.
At present, antibiotics and antifungal medicines are main means for treating Bacterial Vaginitis (BV) and mycotic vaginitis (VVC), but the antibiotics and antifungal medicines are adopted to kill vaginal pathogenic bacteria and inhibit the growth of normal beneficial bacteria in the vagina, so that vaginal flora imbalance is caused, and pathogenic bacteria are dominant.
Maintain the normal flora balance of vagina, and can be used for preventing and treating vaginitis. In the 80 th 20 th century, auxiliary treatment of BV and VVC by using lactobacillus preparations was reported, but not all lactobacilli have the same biological activity, so the using effect is not obvious.
In order to solve the problems in the prior art, the invention aims to provide lactobacillus rhamnosus PB-LR76, lactobacillus reuteri PB-LR09, a probiotic formula thereof, and a preparation method and application of the formula.
The separation rate of the lactobacillus in the vaginal secretion specimen of the healthy female is as high as 80-100%. Research shows that a plurality of flora exist in the vagina of a female, and the dominant bacteria are lactobacillus; the number of lactobacillus in vagina keeps a harmonious and dynamic balance with the host and the environment. It has been found that orally ingested strains of lactobacillus can enter the gastrointestinal tract in the form of viable bacteria, pass rectally into the vagina, and colonize the vagina to exert their biological effects. Therefore, the lactobacillus is supplemented to help restore the microecological balance of the vagina, so that the growth and the propagation of pathogenic bacteria are inhibited to play a role in 'killing bacteria'. The lactobacilli can inhibit pathogenic bacteria in the vagina, and the action of the lactobacilli is mainly realized by producing bacteriostatic substances such as lactic acid, hydrogen peroxide, bacteriocin and the like, and the bacteriostatic substances only selectively act on a few pathogenic bacteria and do not destroy the balance of the whole vaginal flora.
Based on the principle, the invention relates to a probiotic formula for improving female vaginitis and application thereof, wherein the probiotic formula comprises a strain of Lactobacillus rhamnosus PB-LR76(Lactobacillus rhamnosus) which is preferably obtained, the strain number is PB-LR76, the strain is preserved in China center for type culture Collection, and the preservation number is CCTCC NO: m2018887; lactobacillus reuteri PB-LR09(Lactobacillus reuteri) with the strain number of PB-LR09 is preserved in China center for type culture Collection with the preservation number of CCTCC NO: m2018888. The two strains are preferably selected from Bifidobacterium lactis with strain number HH-BA68, and can be used for improving female Bacterial Vaginitis (BV) and mycotic vaginitis (VVC).